149 related articles for article (PubMed ID: 9146778)
1. Daily omeprazole surpasses intermittent dosing in preventing relapse of oesophagitis: a US multi-centre double-blind study.
Sontag SJ; Robinson M; Roufail W; Hirschowitz BI; Sabesin SM; Wu WC; Behar J; Peterson WL; Kranz KR; Tarnawski A; Dayal Y; Berman R; Simon TJ
Aliment Pharmacol Ther; 1997 Apr; 11(2):373-80. PubMed ID: 9146778
[TBL] [Abstract][Full Text] [Related]
2. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
[TBL] [Abstract][Full Text] [Related]
3. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis.
Hatlebakk JG; Berstad A
Aliment Pharmacol Ther; 1997 Apr; 11(2):365-72. PubMed ID: 9146777
[TBL] [Abstract][Full Text] [Related]
4. Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo.
Bardhan KD; Cherian P; Vaishnavi A; Jones RB; Thompson M; Morris P; Brooks A; D'Silva J; Gillon KR; Wason C; Patterson J; Polak J; Bishop A
Gut; 1998 Oct; 43(4):458-64. PubMed ID: 9824569
[TBL] [Abstract][Full Text] [Related]
5. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.
Dent J; Yeomans ND; Mackinnon M; Reed W; Narielvala FM; Hetzel DJ; Solcia E; Shearman DJ
Gut; 1994 May; 35(5):590-8. PubMed ID: 8200548
[TBL] [Abstract][Full Text] [Related]
6. Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study.
Laursen LS; Havelund T; Bondesen S; Hansen J; Sanchez G; Sebelin E; Fenger C; Lauritsen K
Scand J Gastroenterol; 1995 Sep; 30(9):839-46. PubMed ID: 8578181
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.
Richter JE; Peura D; Benjamin SB; Joelsson B; Whipple J
Arch Intern Med; 2000 Jun; 160(12):1810-6. PubMed ID: 10871975
[TBL] [Abstract][Full Text] [Related]
8. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
[TBL] [Abstract][Full Text] [Related]
9. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group.
Bate CM; Booth SN; Crowe JP; Mountford RA; Keeling PW; Hepworth-Jones B; Taylor MD; Richardson PD
Gut; 1995 Apr; 36(4):492-8. PubMed ID: 7737552
[TBL] [Abstract][Full Text] [Related]
10. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
Thjodleifsson B; Beker JA; Dekkers C; Bjaaland T; Finnegan V; Humphries TJ
Dig Dis Sci; 2000 May; 45(5):845-53. PubMed ID: 10795744
[TBL] [Abstract][Full Text] [Related]
11. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.
Mee AS; Rowley JL
Aliment Pharmacol Ther; 1996 Oct; 10(5):757-63. PubMed ID: 8899084
[TBL] [Abstract][Full Text] [Related]
12. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Adler J; Eklund S
Aliment Pharmacol Ther; 2005 Nov; 22(9):803-11. PubMed ID: 16225489
[TBL] [Abstract][Full Text] [Related]
13. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
Caos A; Breiter J; Perdomo C; Barth J
Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056
[TBL] [Abstract][Full Text] [Related]
14. Prevention of erosive oesophagitis relapse with pantoprazole.
Richter JE; Fraga P; Mack M; Sabesin SM; Bochenek W;
Aliment Pharmacol Ther; 2004 Sep; 20(5):567-75. PubMed ID: 15339328
[TBL] [Abstract][Full Text] [Related]
15. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable?
Boccia G; Manguso F; Miele E; Buonavolontà R; Staiano A
Am J Gastroenterol; 2007 Jun; 102(6):1291-7. PubMed ID: 17319927
[TBL] [Abstract][Full Text] [Related]
16. Treatment and prevention of relapse of mild oesophagitis with omeprazole and cisapride: comparison of two strategies.
Kimmig JM
Aliment Pharmacol Ther; 1995 Jun; 9(3):281-6. PubMed ID: 7654890
[TBL] [Abstract][Full Text] [Related]
17. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators.
Kahrilas PJ; Falk GW; Johnson DA; Schmitt C; Collins DW; Whipple J; D'Amico D; Hamelin B; Joelsson B
Aliment Pharmacol Ther; 2000 Oct; 14(10):1249-58. PubMed ID: 11012468
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a pectin-based anti-reflux agent on acid reflux and recurrence of symptoms and oesophagitis in gastro-oesophageal reflux disease.
Havelund T; Aalykke C; Rasmussen L
Eur J Gastroenterol Hepatol; 1997 May; 9(5):509-14. PubMed ID: 9187886
[TBL] [Abstract][Full Text] [Related]
19. Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole.
Pilotto A; Leandro G; Franceschi M;
Aliment Pharmacol Ther; 2003 Jun; 17(11):1399-406. PubMed ID: 12786634
[TBL] [Abstract][Full Text] [Related]
20. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis.
Bate CM; Green JR; Axon AT; Murray FE; Tildesley G; Emmas CE; Taylor MD
Aliment Pharmacol Ther; 1997 Aug; 11(4):755-63. PubMed ID: 9305486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
